Stress in cells activates hepatitis viruses
Substances which suppress the immune system while simultaneously keeping viral infections in check would be an ideal drug for organ transplant recipients. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now demonstrated that specific substances with such an activity profile caused a state of stress in cells which promotes the replication of hepatitis B viruses.
Electron microscopic picture of hepatitis B viruses
© Thomas Bock, Hanswalter Zentgraf, German Cancer Research Center
People who have received a donor organ need lifelong immunosuppressant drugs to keep their immune system from attacking the foreign tissue. However, with a suppressed immune system, many infectious agents turn into a threat. Infections such as with human cytomegalovirus and a certain type of human polyomavirus frequently cause complications in transplant recipients. For these patients it would therefore be particularly beneficial to have substances that suppress the immune system and exert an antiviral activity at the same time – thus killing two birds with one stone.
Jointly with colleges from Heidelberg University Hospital of Internal Medicine, researchers Professors Karin and Felix Hoppe-Seyler of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now tested a number of drugs with such an activity profile. They also tested the substances in liver cells infected with hepatitis B viruses (HBV) in the culture dish. The result: Liver cells that had been treated even produced considerably more viral offspring than untreated ones.
The substances under investigation inhibit the synthesis of nucleotides, which are the basic building blocks of DNA. This is how they exert their immunosuppressive effect: They slow down multiplication of immune cells because these lack building material for duplicating their genetic material. “The lack of DNA building blocks can cause a kind of stress in specific cells, which shows in the activation of a stress protein called p38”, says Felix Hoppe-Seyler. “In liver cells, p38 very effectively activates the replication of hepatitis B viruses. “
The findings of the DKFZ researchers are a definite indication that administering these drugs in transplant recipients bears risks. Liver transplants, in particular, often have to be done because the body’s own organ has been destroyed by hepatitis B viruses. In such cases, drug-induced activation of remaining HBV in the body may lead to the donor organ being attacked by hepatitis B viruses again.
Felix Hoppe-Seyler suspects that besides the three substances the group has investigated there are other substances which also cause an activation of p38. “In cancer patients being treated by chemotherapy, there is often a reactivation of chronic HBV infections. This has always been put down to their weakened immune system. We will now investigate whether this may also be due to activation of stress protein p38,” said the virologist outlining the goals of his further research.
Karin Hoppe-Seyler, Peter Sauer, Claudia Lohrey and Felix Hoppe-Seyler: The Inhibitors of Nucleotide Biosynthesis Leflunomide, FK778, and Mycophenolic Acid Activate Hepatitis B Virus Replication In Vitro. Hepatology, 2012, DOI: 10.1002/hep.25602
A picture for this press release is available at:
http://www.dkfz.de/de/presse/pressemitteilungen/2012/images/hbv-partikel-sw.jpg
Picture caption: Electron microscopic picture of hepatitis B viruses. Thomas Bock, Hanswalter Zentgraf, German Cancer Research Center.
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.
To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.
